Maravai LifeSciences (MRVI) Misses Q2 EPS by 5c, provides guidance

Maravai LifeSciences (NASDAQ: MRVI) reported Q2 EPS of ($0.05), $0.05 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $73.4 million versus the consensus estimate of $71.64 million.

GUIDANCE:

Maravai LifeSciences sees FY2024 revenue of $265-285 million, versus the consensus of $275.4 million. Adjusted EBITDA (non-GAAP) margins are now expected to be in the range of 20% to 22%.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Labcorp makes RNA-based colorectal cancer home test available nationwide
• Gladiator Metals raises C$35M in BlackRock-led private placement